Genzyme's CEO spent a good part of Monday burnishing the prospects of their experimental MS drug alemtuzumab, and thereby the value of the big biotech. With Sanofi so far unwilling to budge from its $69 offer, and Genzyme just as insistent on refusing to entertain such a price, Henri Termeer was limited to making fresh enthusiastic noises about a possible contingent value rights deal. But for now there's nothing new on prospective talks with Sanofi. "Clearly," said Termeer, "we will have conversations at the right moment...It can't go on forever."Story